MGI Tech Celebrates 10 Years of Innovation, Empowering 3,560 Users Across Six Continents

Why It Matters

By slashing sequencing costs and bundling end‑to‑end multi‑omics tools, MGI accelerates the transition of genomics from niche labs to routine clinical and agricultural applications, reshaping global health and biotech markets.

Key Takeaways

• MGI serves 3,560 users across six continents with 5,300 installations.
• T20×2 platform cuts whole-genome sequencing cost below $100 per genome.
• Integrated short‑read, long‑read, and spatial omics ecosystem after acquisitions.
• AI‑driven G400RS FluoXpert Vision uses DeepSeek V3 LLM for prompts.
• Industry targets $10 per genome, unlocking preventive medicine and surveillance.

Pulse Analysis

MGI Tech’s decade‑long evolution illustrates how sequencing hardware has shifted from bulky, expensive instruments to scalable, cost‑effective platforms. The T20×2 “Super Sequencing Factory” can process up to 50,000 human genomes a year, driving per‑genome pricing below $100—a benchmark that has opened population‑scale projects in oncology, rare‑disease diagnostics, and public‑health surveillance. This price compression mirrors broader market dynamics where economies of scale, automation, and modular design are redefining the economics of genomic research.

Beyond raw throughput, MGI’s strategic acquisitions of STOmics and CycloneSEQ have created a rare, single‑vendor ecosystem that spans short‑read, long‑read, and spatial‑omics modalities. Coupled with AI‑enabled tools like the G400RS FluoXpert Vision, which leverages the DeepSeek V3 large language model for workflow orchestration, the company delivers end‑to‑end data pipelines that reduce manual variability and accelerate insight generation. Intelligent laboratory solutions such as the SP‑960 automation line and DNBelab C Series single‑cell platforms further embed reproducibility into high‑throughput settings, positioning MGI as a full‑stack provider for multi‑omics research.

Looking forward, the industry’s ambition to bring whole‑genome sequencing down to $10 per genome could transform preventive medicine, enable real‑time pathogen monitoring, and support precision agriculture on a global scale. MGI’s focus on generative lab intelligence, modular hardware, and AI‑driven analytics equips it to meet this challenge, potentially democratizing access to genomic data for institutions previously constrained by cost or technical complexity. As biological data volumes explode, the convergence of large‑scale sequencing, artificial intelligence, and integrated lab ecosystems will likely become the backbone of next‑generation biotech innovation.